4th Targeted Radiopharmaceuticals Europe

Success of prostate cancer treatments has triggered a seismic shift in the status of the TRP field over the last year and sparked more research investment than ever before.

The Targeted Radiopharmaceuticals Summit Europe returns for its fourth year as the only event to address the needs of drug developers at all development stages, from both medical and operational perspectives.

Overcome the technical, logistical, and translational hurdles of radionuclide therapy development. This event will bring together clinical, logistical and manufacturing experts from radiopharma and academia to help you accelerate your development programmes, tackle supply chain issues and harness alpha- and beta- emitting radionuclides to take on new cancers.

Prices:
Conference + 2 Workshops - Drug Developer EUR 3797.00
Conference + 1 Workshop - Drug Developer EUR 3298.00
Conference Only - Drug Developer EUR 2799.00
Conference + 2 Workshops - Solution Provider & Vendor EUR 4697.00
Conference + 1 Workshop - Solution Provider & Vendor EUR 4098.00
Conference only - Solution Provider & Vendor EUR 3499.00
Conference + 2 Workshops - Academic & Non-for-profit EUR 2997.00
Conference + 1 Workshop - Academic & Non-for-profit EUR 2698.00
Conference Only - Academic & Non-for-profit EUR 2399.00

Speakers: Monideepa Roy, Vice President - Corporate, Research & Development, Actinium Pharmaceuticals, Eftychia Koumarianou, Director - Pre-clinical & Pharmacy, ABX-CRO, Stanley Satz, Chairman & Chief Scientific Officer, Advanced Innovative Partners, Andreas Kluge, Owner & Lead Consultant, ABX-CRO, Manfred Rüdiger, Chief Executive Officer & Managing Director, Ariceum Therapeutics, Michael Zalutsky, Professor of Radiology & Director, Radiopharmaceutical Chemistry Laborator, Duke University, Jeff Kovacs, Head of Oncology Research, Aktvis Oncology, Sheamus Gleason, Executive Vice President, Clarity Pharmaceuticals, Friedmund Bachmann, Director - Chemistry, Manufacturing, Control & Biologics, OncoOne, Stig Palm, Researcher, Department of Radiation Physics, John Carney, Chief Executive Officer, itheranostics, Jean-François, Gestin Head of Chemistry & Radiochemistry, Inserm Lille Neuroscience & Cognition Research Centre, Jan A. Alfheim, Chief Executive Officer, Oncoinvent, Adrien Reymond, Radiopharmaceuticals Expert Consultant, READ Pharma, Chris Pak, President & Chief Executive Officer, Molecular Targeting Technologies, Cyril Berthet, Director of Pharmaco-Imaging Unit & MRT Department, Oncodesign SA, Jakub Simecek, Chief Executive Officer, TRIMT, Marc Robillard, Chief Executive Officer & Founder, Tagworks Pharmaceuticals, James Nagarajah, Assistant Professor, Radboudumc, Riccardo Canevari, Chief Executive Officer, Radiopharm Theranostics, Lucy Morgan, Associate Director of Research & Policy, The Health Policy Partnership, Noble George, Sr Director Imaging Science & Operations, POINT Biopharma, Alex Jackson, Head of Research & Development, Theragnostics, Michael Schultz, Chief Science Officer, Viewpoint Molecular Targeting